Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631588 · ClinicalTrials.gov registry record · Phase 1
Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines
A Phase 1 study of Facial Fine Lines, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
- 5
- Study locations
NCT04631588: Completed Phase 1 study of Facial Fine Lines, sponsored by Allergan.
NCT04631588 is a Phase 1 study of Facial Fine Lines that has completed, run by Allergan. The registered enrollment target is 172 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (187% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04631588, a Phase 1 study of Facial Fine Lines, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.
Primary Outcome
Unique number of participants who experience one or more treatment emergent adverse event
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Botox
Study Locations (5)
Florida
- Skin and Cancer Associates, LLP /ID# 225152 - Miami
New York
- Laser & Skin Surgery Center of New York /ID# 225153 - New York
Tennessee
- Tennessee Clinical Research Center /ID# 225151 - Nashville
Texas
- Austin Institute for Clinical Research /ID# 225154 - Pflugerville
Utah
- Advanced Clinical Research /ID# 225155 - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2021-11-03 |
| Phase | Phase 1 |
What the finished NCT04631588 record still lists
NCT04631588 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (187% higher).
The record links to 1 condition, with Facial Fine Lines appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04631588 lists 5 locations in 5 states (Florida, New York, Tennessee).
Frequently Asked Questions
What is clinical trial NCT04631588 about?
NCT04631588 is a clinical study titled "Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines". The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.
What is the current status of trial NCT04631588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2020-11-16. Estimated completion is 2021-11-03.
What conditions does trial NCT04631588 study?
This clinical trial studies the following conditions: Facial Fine Lines.
What interventions are being tested in trial NCT04631588?
The interventions under investigation include: Placebo (DRUG), Botox (DRUG).
Who is sponsoring clinical trial NCT04631588?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04631588 being conducted?
This trial has 5 study locations across Florida, New York, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04631588's enrollment target sits among peer trials
172 324th of 2000 higher than 1,677 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI